The 2025 Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center (ASC) Payment Systems Rule favorably impacts reimbursement rates for the Park City, Utah-based company’s Revi implantable tibial neuromodulation (iTNM) system.
Revi is an iTNM device implanted near the ankle during a single outpatient procedure. Patients initiate Revi therapy at their convenience by placing a lightweight, wireless wearable around their ankle once daily. This provides stimulation to the posterior tibial nerve, offering relief from urgency urinary incontinence (UUI) symptoms.
The first and only FDA-cleared iTNM system activated by an external wireless wearable for patients with UUI, Revi enables patients to initiate therapy at their convenience.
CMS set the national unadjusted ASC payment rate for Category III CPT code 0817T for 2025. That includes Revi at $19,839, marking a 40% increase from the 2024 rate. For the hospital outpatient setting, the payment increased by 3% to $21,444. BlueWind said this highlights CMS’ recognition of Revi as a unique, effective solution for UUI.
“The CMS decision to increase the reimbursement rate for the Revi System in the ASC setting reflects the growing recognition of iTNM as an effective, minimally invasive therapy for urgency urinary incontinence,” said Steve Armstrong, Chief Financial Officer and General Manager of BlueWind Medical. “This update underscores the proven durability, safety, and patient satisfaction research behind the Revi System as an important and innovative approach to treat this distressing condition.”
